Particle.news
Download on the App Store
4 ARTICLES
·
6d ago

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

The licensing deal makes Zydus the U.S. marketer and keeps Bioeq responsible for manufacturing and supply.

Zydus will focus on Nufymco’s commercialisation across the US market. Credit: cameranest/Shutterstock.com.
Image

Overview

  • Zydus Lifesciences Global FZE entered a U.S. licensing and commercialization agreement with Switzerland-based Bioeq for NUFYMCO.
  • The FDA approved the Biologics License Application for NUFYMCO on December 18, 2025, designating it an interchangeable biosimilar to Lucentis (ranibizumab).
  • Under the agreement, Bioeq will handle development, manufacturing, registration and supply, and Zydus will lead U.S. commercialization.
  • Zydus and Bioeq say the collaboration aims to expand access to more affordable ophthalmology care through a high-quality biosimilar option.
  • The U.S. market opportunity for ranibizumab biosimilars is estimated at about $210 million, and the pact extends Zydus’s recent biosimilar push that includes a Keytruda (pembrolizumab) biosimilar deal.